标题
Allogeneic transplantation for CML in the TKI era: striking the right balance
作者
关键词
-
出版物
Nature Reviews Clinical Oncology
Volume 13, Issue 2, Pages 79-91
出版商
Springer Nature
发表日期
2015-11-17
DOI
10.1038/nrclinonc.2015.193
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Long-Term Survival after Transplantation of Unrelated Donor Peripheral Blood or Bone Marrow Hematopoietic Cells for Hematologic Malignancy
- (2015) Mary Eapen et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors
- (2015) J.H. Lipton et al. LEUKEMIA RESEARCH
- Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials
- (2015) Koji Sasaki et al. Lancet Haematology
- Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study
- (2014) N. P. Shah et al. BLOOD
- Oral Sessions
- (2014) BONE MARROW TRANSPLANTATION
- Comparison of Unrelated Cord Blood Transplantation and HLA-Matched Sibling Hematopoietic Stem Cell Transplantation for Patients with Chronic Myeloid Leukemia in Advanced Stage
- (2013) Changcheng Zheng et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
- (2013) M. Baccarani et al. BLOOD
- Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)
- (2013) E. Jabbour et al. BLOOD
- Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
- (2013) D. M. Ross et al. BLOOD
- Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT
- (2013) A J Innes et al. BONE MARROW TRANSPLANTATION
- Tyrosine Kinase Inhibitors as Initial Therapy for Patients With Chronic Myeloid Leukemia in Accelerated Phase
- (2013) Maro Ohanian et al. Clinical Lymphoma Myeloma & Leukemia
- A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
- (2013) J.E. Cortes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Allogeneic stem cell transplantation for patients with chronic myeloid leukemia: Risk stratified approach with a long-term follow-up
- (2012) Tsila Zuckerman et al. AMERICAN JOURNAL OF HEMATOLOGY
- Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy
- (2012) Anthony Oyekunle et al. ANNALS OF HEMATOLOGY
- Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era
- (2012) E. Warlick et al. BLOOD
- How I treat CML blast crisis
- (2012) R. Hehlmann BLOOD
- Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors
- (2012) A. R. Rossi et al. HAEMATOLOGICA
- Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study
- (2012) F J Giles et al. LEUKEMIA
- Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)
- (2012) B Hanfstein et al. LEUKEMIA
- Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors
- (2012) Claudio Anasetti et al. NEW ENGLAND JOURNAL OF MEDICINE
- Case-matched comparison with standard versus reduced intensity conditioning regimen in chronic myeloid leukemia patients
- (2011) Pervin Topcuoglu et al. ANNALS OF HEMATOLOGY
- Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase
- (2011) Q. Jiang et al. BLOOD
- Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius
- (2011) G. Socie et al. BLOOD
- Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis
- (2011) H J Khoury et al. BONE MARROW TRANSPLANTATION
- Efficacy of combining dasatinib and FLAG-IDA for patients with chronic myeloid leukemia in blastic transformation
- (2011) D. Milojkovic et al. HAEMATOLOGICA
- Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors
- (2011) David Marin et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term outcomes of HLA-matched sibling compared with mismatched related and unrelated donor hematopoietic stem cell transplantation for chronic phase chronic myelogenous leukemia: a single institution experience in China
- (2010) Qi-fa Liu et al. ANNALS OF HEMATOLOGY
- Single-Unit Umbilical Cord Blood Transplantation from Unrelated Donors in Adult Patients with Chronic Myelogenous Leukemia
- (2010) Jaime Sanz et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis
- (2010) V. Gupta et al. BLOOD
- Three decades of transplantation for chronic myeloid leukemia: what have we learned?
- (2010) J. Pavlu et al. BLOOD
- Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations
- (2010) E. Jabbour et al. BLOOD
- Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy
- (2010) A. R. Ibrahim et al. BLOOD
- Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib
- (2010) David Marin et al. JOURNAL OF CLINICAL ONCOLOGY
- Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
- (2010) François-Xavier Mahon et al. LANCET ONCOLOGY
- Exploring chronic myeloid leukemia patients’ reasons for not adhering to the oral anticancer drug imatinib as prescribed
- (2010) Lina Eliasson et al. LEUKEMIA RESEARCH
- Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
- (2010) Giuseppe Saglio et al. NEW ENGLAND JOURNAL OF MEDICINE
- Current role of stem cell transplantation in chronic myeloid leukaemia
- (2009) Alois Gratwohl et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- The blast phase of chronic myeloid leukaemia
- (2009) Richard T. Silver BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV
- (2009) S. Saussele et al. BLOOD
- Risk score for outcome after allogeneic hematopoietic stem cell transplantation
- (2009) Alois Gratwohl et al. CANCER
- Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia
- (2009) D. Milojkovic et al. HAEMATOLOGICA
- Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission
- (2009) John Koreth et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Reduced-intensity allogeneic transplantation combined with imatinib mesylate for chronic myeloid leukemia in first chronic phase
- (2009) Y Luo et al. LEUKEMIA
- Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia
- (2008) S. J. Lee et al. BLOOD
- Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT Toxicity in patients with chronic myelogenous leukemia and philadelphia positive acute lymphoblastic leukemia
- (2008) A Shimoni et al. LEUKEMIA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started